RCMNY
EPRX

Rubric Capital Management (New York)’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Rubric Capital Management (New York)’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.73M Buy
867,424
+176,254
+26% +$1.22M 0.05% 79
2026
Q1 		$5M Buy
+691,170
New +$5.56M 0.05% 78

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Rubric Capital Management (New York)'s EPRX Position: Q2 2026 in Review

Rubric Capital Management (New York) increased its Eupraxia Pharmaceuticals (EPRX) stake by 26% in Q2 2026, buying an estimated $1.22M and bringing the position to 867,424 shares worth $5.73M. The position accounts for 0.05% of the portfolio, ranked #79.

Rubric Capital Management (New York) first reported a position in EPRX in Q1 2026 and has held it in 2 quarters since. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Rubric Capital Management (New York) held 867,424 shares of Eupraxia Pharmaceuticals worth $5.73M as of Q2 2026.
  • Rubric Capital Management (New York) bought 176,254 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $1.22M.
  • Eupraxia Pharmaceuticals made up 0.05% of Rubric Capital Management (New York)'s portfolio in Q2 2026, its #79 holding.
  • Rubric Capital Management (New York) first reported a position in Eupraxia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.